All In Biotech

Drug Trial Radar · NCT00699972

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Last checked: Nov 19, 2026Latest source record: Jan 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

390

Actual

Start

Apr 30, 2008

Primary completion

Oct 19, 2010

Study completion Oct 19, 2010

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Jun 18, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, efficacy and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.

Conditions

  • Refractory Partial Seizures

Interventions

  • E2007 (perampanel)Drug

    8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.

  • E2007 (perampanel)Drug

    12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.

  • PlaceboDrug

    Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases)Time frame: Baseline (Pre-randomization) through Week 19

Locations

97 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • St. Joseph's Hospital And Medical Center

    Phoenix, Arizona

  • Clinical Trials, Inc.

    Little Rock, Arkansas

  • Childrens Hospital Los Angeles

    Los Angeles, California

  • Bright Minds Institute

    San Francisco, California

  • California Pacific Medical Center

    San Francisco, California

  • Mile High Research Center

    Denver, Colorado

  • Children's Research Institute

    Washington D.C., District of Columbia

  • University of Florida Health Sciences, Jacksonville

    Jacksonville, Florida

  • Pediatric Neurology and Epilepsy Center

    Loxahatchee Groves, Florida

  • Site not named

    Loxahatchee Groves, Florida

  • Pediatric Neurology PA

    Orlando, Florida

  • North West Florida Clinical Research Group

    Pensacola, Florida

  • Child Neurology Center Of Nw Florida

    Pensacola, Florida

  • Lovelace Scientific Resources

    Sarasota, Florida

  • Ronald Aung-Din, MD, PC

    Sarasota, Florida

  • Tallahassee Neurological Clinic

    Tallahassee, Florida

  • Pediatric Epilepsy and Neurology Specialists

    Tampa, Florida

  • PANDA

    Atlanta, Georgia

  • Children's Healthcare of Atlanta at Scottish Rite

    Atlanta, Georgia

  • Georgia Neurology and Sleep Medicine Associates

    Suwanee, Georgia

  • Josephson Wallack Munshower Neurology

    Indianapolis, Indiana

  • McFarland Clinic, PC

    Ames, Iowa

  • Via Christi Comprehensive Epilepsy Center

    Wichita, Kansas

  • Site not named

    Wichita, Kansas

  • University of Kentucky Research Foundation

    Lexington, Kentucky

  • Kentucky Neuroscience Research

    Louisville, Kentucky

  • Leonard J. Chabert Medical Center

    Houma, Louisiana

  • Louisiana State University Health Sciences Center

    Shreveport, Louisiana

  • Neurology/Johns Hopkins Hospital

    Baltimore, Maryland

  • Mid-Atlantic Epilepsy and Sleep Center

    Bethesda, Maryland

  • Boston University Medical Center

    Boston, Massachusetts

  • Michigan Neurology Associates, P.C.

    Clinton Township, Michigan

  • Washington University

    St Louis, Missouri

  • Albany Medical College

    Albany, New York

  • Five Towns Neurology, PC

    Cedarhurst, New York

  • Long Island Jewish Medical Center

    New Hyde Park, New York

  • Univeristy of Rochester Strong Epilepsy Center

    Rochester, New York

  • Asheville Neurology Specialists, PA

    Asheville, North Carolina

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.